Patients: 15 480 patients ≥ 40 years of age (mean age 63 y, 63% men) who had any type of diabetes, no known CVD disease, and for whom the benefit of antiplatelet therapy was unclear. Exclusion criteria were a clear indication or contraindication for aspirin and conditions potentially limiting study adherence for ≥ 5 years.
Intervention: Aspirin, 100 mg/d (n = 7740), or placebo tablet (n = 7740). Patients were also randomized to n-3 fatty acid, 1 g/d, or placebo; results of that comparison are not reported here.
Outcomes: Primary efficacy outcome was a composite of serious vascular events (first myocardial infarction, stroke, transient ischemic attack, or death from any vascular cause other than intracranial hemorrhage [ICH]), and primary safety outcome was a composite of major bleeding events (first ICH, sightthreatening bleeding in eye, gastrointestinal [GI] bleeding, or other serious bleeding). Secondary outcomes included GI tract cancer.
Participant follow-up: 99% (intention-to-treat analysis).

Main results
The main results are in the Table.
Conclusion
In patients with diabetes but no known cardiovascular disease, aspirin reduced serious vascular events, but increased major 
Commentary
Prevention of atherothrombotic events is a therapeutic goal for patients with diabetes. The ASCEND trial found that an increased risk for bleeding offset the reduction in CVD events and is consistent with other trials of aspirin for primary prevention (1, 2) . These trials challenge current guidelines (3) and the longheld opinion of many clinicians of the net benefit of aspirin.
Aspirin use in patients with diabetes needs to be individualized after accurate assessment of risk for (athero)thrombosis and hemorrhage. Valid and precise estimators of these risks are urgently needed. For some patients, CV risk is "high enough" to warrant aspirin, especially if bleeding risk is low. Reducing risk for bleeding via gastroprotection, a cost-effective strategy in secondary prevention (4), could further tip the scale in favor of aspirin.
Given differences in the pathophysiology of type 1 and type 2 diabetes, aspirin could have different effects in such patients (5, 6) . In ASCEND, < 6% of patients had type 1 diabetes; these patients might benefit more from aspirin for primary CVD prevention. A final consideration is dosage (100 mg/d in ASCEND trial): The results could partly be attributed to dosage not tailored to bodyweight and to once-vs twice-daily administration. 
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